Type 2 diabetes trials recruiting in Connecticut

All Type 2 diabetes trials nationally

Cities in Connecticut

Recruiting trials in Connecticut

• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
  NCT07351045 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus
  NCT07662044 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Bridgeport
• A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
  NCT07061574 · Phase: Phase 1, Phase 2 · Ages: 9 Years to 20 Years · Sex: All (male and female) · Connecticut: New Haven
• A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
  NCT07282613 · Phase: Phase 3 · Ages: 10 Years to 18 Years · Sex: All (male and female) · Connecticut: New Haven
• A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
  NCT07654374 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Connecticut: Waterbury
• A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
  NCT06739122 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Connecticut: New Haven
• A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
  NCT07282600 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Bridgeport, Hamden
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Waterbury
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Bridgeport, New Haven, Waterbury
• A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
  NCT07662213 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Bridgeport
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Connecticut: Stamford
• Continuous Glucose Monitors (CGMs) for All: Studying the Impact of Expanding CGM Access
  NCT06658067 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Diabetes Learning in Virtual Environments Just in Time for Community Reentry
  NCT05286892 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Storrs, Storrs Mansfield
• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
  NCT07064473 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Connecticut: Bridgeport, Hamden, Stamford
• Effect of the Thrive AI Health App on Lifestyle Behaviors and Quality of Life
  NCT07376655 · Phase: Not applicable (e.g. observational or device study) · Ages: 40 Years and older · Sex: All (male and female) · Connecticut: New Haven
• Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
  NCT07579702 · Phase: Not applicable (e.g. observational or device study) · Ages: 14 Years to 75 Years · Sex: All (male and female) · Connecticut: New Haven
• GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
  NCT07228117 · Phase: Not applicable (e.g. observational or device study) · Ages: 7 Years to 85 Years · Sex: All (male and female) · Connecticut: New Haven
• Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
  NCT07216391 · Phase: Phase 2 · Ages: 4 Years to 34 Years · Sex: All (male and female) · Connecticut: New Haven
• Registry for Stage 2 Type 1 Diabetes
  NCT06481904 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Connecticut: New Haven
• Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
  NCT05776563 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 60 Years · Sex: All (male and female) · Connecticut: New Haven
• Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
  NCT07271186 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Connecticut: New Haven
• Ultrasound Effects on Glycemic Control in T2DM
  NCT05354947 · Phase: Not applicable (e.g. observational or device study) · Ages: 21 Years to 75 Years · Sex: All (male and female) · Connecticut: New Haven